|
Switzerland-Fl-Fl Azienda Directories
|
Azienda News:
- Jason Mouabbi Highlights ILC Research at ASCO 2025 and Calls for . . .
Key Findings: Whole-exome sequencing of 617 samples showed unique CNV patterns and enriched APOBEC activity in histomolecular ILC These tumors had lower HRD but higher TMB compared to NST, suggesting therapeutic vulnerabilities 2
- LBCA Scientific Advisory Board Chair, Dr. Mouabbi Presents ILC Research . . .
Dr Mouabbi’s abstract titled, “The multiomic tumor microenvironment landscape of invasive lobular carcinoma of the breast” discusses the tumor microenvironment (TME) in invasive lobular carcinoma (ILC) and its critical role in tumor progression and therapeutic response
- IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell . . . - PubMed
We explored the theory that targeting of IL2 to CD8+ T cells, which are key antitumor effectors, could enhance its therapeutic index To this aim, we developed AB248, a CD8 cis-targeted IL2 that demonstrates over 500-fold preference for CD8+ T cells over natural killer and regulatory T cells (Tregs), which may contribute to toxicity and
- Jason MOUABBI | Professor (Assistant) | Doctor of Medicine | University . . .
Jason MOUABBI, Professor (Assistant) | Cited by 92 | of University of Texas MD Anderson Cancer Center, Texas (MD Anderson) | Read 37 publications | Contact Jason MOUABBI
- LBCA Welcomes Dr. Jason Mouabbi As New Scientific Advisory Board Chair . . .
In August 2023, Jason Mouabbi, MD, assumed the role of chair of the Lobular Breast Cancer Alliance (LBCA) Scientific Advisory Board (SAB) Dr Mouabbi is assistant professor of breast medical oncology at The University of Texas MD Anderson Cancer Center, Houston, Texas
- IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy
Strong IL-2 receptor stimulation of antigen-activated CD8 + T cells induces a unique gene expression program in which the cells harbor a superior cytotoxicity and anticancer antiviral potential This effect can be achieved by exogenous IL-2-based therapy or depletion of Tregs
- Finding and filling the knowledge gaps in mechanisms of T cell . . . - Nature
In this Review, we describe current gaps in our knowledge about T cell-mediated immune responses to M tuberculosis and discuss how recent technologies, including multiphoton intravital microscopy
- Jason A. Mouabbi: 5 ILC Abstracts will be presented at ASCO24 as Poster . . .
Presenter: Jason A Mouabbi (MD Anderson Cancer Center), BostonGeneCorp Data: MxIF on 2,139,084 cells from FFPE whole-slide tissues Findings: Detailed multiomic analysis reveals 40% of ILC samples are immune enriched (potential for immunotherapy) and 30% are highly vascularized (potential for anti-angiogenesis therapy)
- IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses . . .
To this aim, we developed AB248, a CD8 cis -targeted IL2 that demonstrates over 500-fold preference for CD8 + T cells over natural killer and regulatory T cells (Tregs), which may contribute to toxicity and immunosuppression, respectively
- Dr. Jason Mouabbi Hosts Webinar Focusing on ILC
During the presentation, the doctors defined invasive lobular carcinoma (ILC), discussed its epidemiology, and described how ILC is different from lobular carcinoma in situ and invasive ductal carcinoma The webinar also covered a discussion of the treatments for ILC including surgery, chemotherapy, and endocrine therapy
|
|